Use of recombinant thrombomodulin in disseminated intravascular coagulation complicated hemophagocytic lymphohistiocytosis

Indian Journal of Pediatrics

Volumn 81, Issue 3, 2014, Pages 288-291

  Yamamoto, Masaki ^a   Hori, Tsukasa ^a   Hatakeyama, Naoki ^a   Igarashi, Keita ^a   Inazawa, Natsuko ^a   Tsutsumi, Hiroyuki ^a   Suzuki, Nobuhiro ^b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO MEDICAL CENTER   (Japan)

Author keywords

DIC; EBV HLH; Immunochemotherapy; Recombinant thrombomodulin (rTM)

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; CYCLOSPORIN A; DEXAMETHASONE; ETOPOSIDE; HEPARIN; INTERLEUKIN 2 RECEPTOR; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; NAFAMSTAT MESILATE; RECOMBINANT THROMBOMODULIN; RECOMBINANT PROTEIN; THROMBOMODULIN;

ADD ON THERAPY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW EXAMINATION; CASE REPORT; CYTOTOXIC T LYMPHOCYTE; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG USE; FEMALE; HEMOPHAGOCYTIC SYNDROME; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; EPSTEIN BARR VIRUS INFECTION; INFANT; TREATMENT OUTCOME;

DISSEMINATED INTRAVASCULAR COAGULATION; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; INFANT; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; RECOMBINANT PROTEINS; THROMBOMODULIN; TREATMENT OUTCOME;

EID: 84898545704     PISSN: 00195456     EISSN: 09737693     Source Type: Journal    
DOI: 10.1007/s12098-013-1145-1     Document Type: Article

References (9)

1. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124-31. (Pubitemid 44958267)
2. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33:35-9.
3. Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93:1869-74. (Pubitemid 29128488)
4. Imashuku S, Teramura T, Tauchi H, Ishida Y, Otoh Y, Sawada M, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica. 2004;89:183-8. (Pubitemid 38796492)
5. Karapinar B, Yilmaz D, Balkan C, Akin M, Ay Y, Kvakli K. An unusual cause of multiple organ dysfunction syndrome in the pediatric intensive care unit: Hemophagocytic lymphohistiocytosis. Pediatr Crit Care Med. 2009;10:285-90.
6. Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007;86:58-65. (Pubitemid 47204491)
7. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost. 1999;82:718-21.
8. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007;5:31-41. (Pubitemid 44921064)
9. Ogawa E, Yagasaki H, Kato M, Shichino H, Chin M, Mugishima H. Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin. Br J Haematol. 2010;149:911-12.